Philip Greenberg
Professor
Medicine & Immunotherapy
Fred Hutchinson Cancer Rearch Center
United States of America
Biography
Dr. Greenberg graduated from Washington University with a degree in biology. He received his M.D. summa cum laude from the State University of New York, Downstate Medical Center, in 1971. After completing postdoctoral training at the University of California at San Diego, he joined the Fred Hutchinson Cancer Research Center and the Division of Oncology at the University of Washington in 1976. He is currently the Head of the Program in Immunology at the Fred Hutchinson Cancer Research Center. Dr. Greenberg has served on the editorial boards of multiple journals, including Journal of Immunology, Gene Therapy, Clinical Cancer Research and Molecular Therapy, and currently serves on the boards of Cancer Immunology and Immunotherapy and Cancer Cell and is Editor-In-Chief of Cancer Immunology Research. Dr. Greenberg currently also serves on multiple Scientific Advisory Boards, including for the University of Chicago Cancer Center, the MD Anderson Cancer Center, the Johns Hopkins Cancer Center, the Cancer Research Institute, and the Ludwig Institute for Cancer Research.
Research Interest
The overall goals of the Greenberg laboratory are to 1) elucidate principles underlying T cell recognition of viruses and cancer cells, 2) determine why such responses often fail to eliminate the viral pathogen or malignancy, and 3) develop cellular and molecular approaches to manipulate cellular immunity and thereby effectively treat human viral and malignant diseases
Publications
-
Stromnes IM, Blattman JN, Tan X, Jeevanjee S, Gu H, Greenberg PD (Oct 2010) Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice., The Journal of clinical investigation, 120 (10), 3722-34
-
Rhee EG, Blattman JN, Kasturi SP, Kelley RP, Kaufman DR, Lynch DM, La Porte A, Simmons NL, Clark SL, Pulendran B, Greenberg PD, Barouch DH (Jan 2011) Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors., Journal of virology, 85 (1), 315-23
-
Kuball J, de Boer K, Wagner E, Wattad M, Antunes E, Weeratna RD, Vicari AP, Lotz C, van Dorp S, Hol S, Greenberg PD, Heit W, Davis HL, Theobald M (Feb 2011) Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909., Cancer immunology, immunotherapy : CII, 60 (2), 161-71
-
Wölfl M, Merker K, Morbach H, Van Gool SW, Eyrich M, Greenberg PD, Schlegel PG (Feb 2011) Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy., Cancer immunology, immunotherapy : CII, 60 (2), 173-86
-
Stone JD, Aggen DH, Chervin AS, Narayanan S, Schmitt TM, Greenberg PD, Kranz DM (May 2011) Opposite Effects of Endogenous Peptide-MHC Class I on T Cell Activity in the Presence and Absence of CD8., Journal of immunology (Baltimore, Md. : 1950), 186 (9), 5193-200
